Keywords: dainippon, sumitomo, debuts, three-year, plan, japanese, drugmaker
Dainippon Sumitomo debuts three-year plan
Article | 12 March 2007
Japanese drugmaker Dainippon Sumitomo expects to establish an independent marketing organization for its schizophrenia drug lurasidone (SM-13496) in the USA ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
